The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis
Open accessAbstract
Aims: Angiopoietin-like protein 3 (ANGPTL3) and 4 (ANGPTL4) inhibit lipoprotein lipase (LPL) and represent emerging drug targets to lower circulating triglycerides and reduce cardiovascular risk. To investigate the molecular effects of genetic mimicry of ANGPTL3 and ANGPTL4 inhibition and compare them to the effects of genetic mimicry of LPL enhancement. Methods and results: Associations of genetic variants in ANGPTL3 (rs11207977-T), ANGPTL4 (rs116843064-A), and LPL (rs115849089-A) with an extensive serum lipid and metabolite profile (208 measures) were characterized in six cohorts of up to 61 240 participants. Genetic associations with anthropometric measures, glucose-insulin metabolism, blood pressure, markers of kidney function, and cardiometabolic endpoints via genome-wide summary data were also explored. ANGPTL4 rs116843064-A and LPL rs115849089-A displayed a strikingly similar pattern of associations across the lipoprotein and lipid measures. However, the corresponding associations with ANGPTL3 rs11207977-T differed, including those for low-density lipoprotein and high-density lipoprotein particle concentrations and compositions. All three genotypes associated with lower concentrations of an inflammatory biomarker glycoprotein acetyls and genetic mimicry of ANGPTL3 inhibition and LPL enhancement were also associated with lower C-reactive protein. Genetic mimicry of ANGPTL4 inhibition and LPL enhancement were associated with a lower waist-to-hip ratio, improved insulin-glucose metabolism, and lower risk of coronary heart disease and type 2 diabetes, whilst genetic mimicry of ANGPTL3 was associated with improved kidney function. Conclusions: Genetic mimicry of ANGPTL4 inhibition and LPL enhancement have very similar systemic metabolic effects, whereas genetic mimicry of ANGPTL3 inhibition showed differing metabolic effects, suggesting potential involvement of pathways independent of LPL. Genetic mimicry of ANGPTL4 inhibition and LPL enhancement were associated with a lower risk of coronary heart disease and type 2 diabetes. These findings reinforce evidence that enhancing LPL activity (either directly or via upstream effects) through pharmacological approaches is likely to yield benefits to human health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Genetically proxied levels of lipids were significantly associated with CAD33,34”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [34]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“CETP variants in the China Kadoorie Biobank that were strongly associated with HDL-C, but not with apolipoprotein B, did not associate with CVD 77 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [77]
Experimental — accuracy not yet measuredIn the citing paper
“such SBP associations have not been identified in drug-target MRs using HDL-C raising variants in CETP 79 77 , for reasons that are unclear.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677
Efficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159 · cited 1×
“Recent genetic studies and randomized controlled trials indicate a causal role for inflammation in CVDs, including findings from genetic studies of the interleukin-6 receptor and phase III clinical trials of antiinflammatory drugs for the treatment of CHD, such as CANTOS trial of canakinumab,(15) a monoclonal antibody…”
BackgroundPhenoScanner: a database of human genotype-phenotype associations.
Staley, J. R., Blackshaw, J., Kamat, M. A., Ellis, S., Surendran, P., Sun, B. B., Paul, D. S., Freitag, D., Burgess, S., Danesh, J., et al. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw373 · Cited by 1,479
Self-citationGenetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703
Self-citationWürtz, P., Kangas, A. J., Soininen, P., Lawlor, D. A., Davey Smith, G., & Ala-Korpela, M. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx016 · Cited by 686
Self-citation
Cited by
Small molecule metabolites: discovery of biomarkers and therapeutic targets
Qiu, S., Cai, Y., Yao, H., Lin, C., Xie, Y., Tang, S., & Zhang, A. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01399-3 · Cited by 884
Richardson, T. G., Leyden, G. M., Wang, Q., Bell, J. A., Elsworth, B., Davey Smith, G., & Holmes, M. V. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001547 · Cited by 304
Self-citationHolmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Self-citationLi, Z., Zhang, B., Liu, Q., Tao, Z., Ding, L., Guo, B., Zhang, E., Zhang, H., Meng, Z., Guo, S., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104543 · Cited by 148
Genetics of coronary artery disease in the post‐GWAS era
Chen, Z., & Schunkert, H. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13362 · Cited by 115
Metadata
- Authors
- Wang, Q., Oliver-Williams, C., Raitakari, O. T., Viikari, J., Lehtimäki, T., Kähönen, M., Järvelin, M.-R., Salomaa, V., Perola, M., Danesh, J., Kettunen, J., Butterworth, A. S., Holmes, M. V., & Ala-Korpela, M.
- Affiliations
- Baker Heart and Diabetes Institute (AU)
- MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge , Cambridge, UK
- University of Turku (FI)
- Tampere University (FI)
- Oulu University Hospital (FI)
- Finnish Institute for Health and Welfare (FI)
- University of Helsinki (FI)
- University of Cambridge (GB)
- National Institute for Health and Care Research (GB)
- Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu , Oulu, Finland
- Corresponding author
- Wang, Qin
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-12-22
- Volume
- 42
- Issue
- 12
- Pages
- 1160-1169
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC7982288
- OpenAlex
- W3111241027
- Cited by
- 89
- References
- 22
- Citations by year
- 2026: 5 · 2025: 18 · 2024: 22 · 2023: 29 · 2022: 7 · 2021: 7
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Heart Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UTUPub (University of Turku) (submittedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by-nc)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- The Academy of Finland (297338, 307247, 322098, 286284, 134309, 126925, 121584, 124282, 129378, 117787, 41071)
- Novo Nordisk foundation (NNF17OC0027034, NNF17OC0026062)
- Oulu Health and Wellfare Center
- Social Insurance Institution of Finland
- Competitive State Research Financing of the Expert Responsibility area of Kuopio
- ERDF European Regional Development Fund (539/2010: A31592)
- EU Horizon 2020 (633595, 755320)
- EU Research Council (742927)
- Sigrid Juselius
- Finnish Cardiovascular Research
- Juho Vainio
- Paavo Nurmi
- Finnish Cultural
- Tampere Tuberculosis
- Emil Aaltonen
- Yrjö Jahnsson
- Signe and Ane Gyllenberg
- Finnish Diabetes Research
- British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512)
- National Institute for Health Research Oxford Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- ANGPTL3, ANGPTL4, lipoprotein lipase, triglycerides, lipid profile, glycoprotein acetyls, C-reactive protein, waist-to-hip ratio, renal function, coronary artery disease, type 2 diabetes, cardiovascular risk
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 4, Angiopoietin-Like Protein 3, Diabetes Mellitus, Type 2, Pharmaceutical Preparations, Humans, Angiopoietins, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa972
- The paper
- Wang, Q., Oliver-Williams, C., Raitakari, O. T., Viikari, J., Lehtimäki, T., Kähönen, M., Järvelin, M.-R., Salomaa, V., Perola, M., Danesh, J., Kettunen, J., Butterworth, A. S., Holmes, M. V., & Ala-Korpela, M. (2021). Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa972
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.